- ProBio has entered into an exclusive global licensing agreement with South Korean biotechnology company AbTis, granting it rights to develop and commercialize a discovery-stage therapeutic antibody asset targeting oncology.
- AbTis plans to use its proprietary AbClick® site-specific conjugation platform to advance the antibody asset toward development as a next-generation antibody-drug conjugate (ADC).
ProBio, a global contract research, development and manufacturing organization (CRDMO), has entered into an exclusive global licensing agreement with South Korean biotechnology company AbTis, a subsidiary of Dong-A ST. Under the agreement, AbTis will receive exclusive global rights to develop and commercialize a discovery-stage therapeutic antibody asset generated through ProBio’s biologics discovery and development capabilities. The asset targets an undisclosed oncology target.
AbTis plans to use the antibody asset to expand its pipeline in bispecific antibody-drug conjugates (ADCs). The company will leverage its proprietary AbClick® site-specific conjugation platform to advance the asset toward development as a next-generation ADC. The platform is designed to enable controlled, site-specific antibody conjugation.
The agreement includes an upfront payment to ProBio, potential development and commercial milestone payments, and royalties on future sales. The financial terms and the specific oncology target were not disclosed in the announcement.
“The agreement demonstrates the company’s strategy of generating biologics assets that can progress into therapeutic development.”
ProBio CEO Allen Guo
“The company plans to use its AbClick® platform to advance the antibody asset toward ADC development.”
AbTis CEO Dr. Hyungsuk Choi
The agreement combines ProBio’s biologics discovery and development capabilities with AbTis’ site-specific conjugation technology. ProBio also provides development and manufacturing capabilities as part of its CRDMO services.
